Phil Pesta serves as Vice President - Operations of the Company. He has served as our Vice President of Operations since July 2011. Mr. Pesta has more than 20 years of experience in the medical device industry, primarily in manufacturing and operations roles. Before joining our company, Mr. Pesta was with Boston Scientific. He was most recently responsible for developing the operations transfer plan for the divestiture of their neurovascular division to Stryker Corporation. Prior to that, Mr. Pesta held simultaneous roles as Director of Engineering at Boston Scientific’s electrophysiology division and Plant Manager at the embolic protection division. Earlier in his career, Mr. Pesta held positions in project management and manufacturing engineering at other companies, including Conceptus, Novare Surgical Systems, Medtronic Anneurx and Modified Polymer Components. He has facilitated the commercial launch of multiple products and is listed as an inventor on three U.S. patents. Mr. Pesta earned a Bachelor of Arts Degree in General Design Studies from San Jose State University.
As the Vice President - Operations of BioCardia, the total compensation of Phil Pesta at BioCardia is 276,000$. There are 5 executives at BioCardia getting paid more, with Peter Altman having the highest compensation of 677,501$.
Phil Pesta is 53, he's been the Vice President - Operations of BioCardia since 2011. There are 12 older and 1 younger executives at BioCardia. The oldest executive at BioCardia Inc. is Simon Stertzer, 83, who is the Independent Chairman of the Board.
Phil's mailing address filed with the SEC is 125 Shoreway Rd, San Carlos, CA 94070, USA.
Over the last 8 years, insiders at BioCardia have traded over 2,555,815$ worth of BioCardia stock and bought 6,474,371 units worth 6,325,055$ . The most active insiders traders include Phillip Md Et Al Frost Gamm...、Simon H Stertzer、Richard M Krasno. On average, BioCardia executives and independent directors trade stock every 48 days with the average trade being worth of 1,321,186$. The most recent stock trade was executed by Phillip Md Et Al Frost Gamm... on 19 January 2024, trading 129,802 units of BCDA stock currently worth 55,815$.
we are a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. biocardia is developing proprietary comprehensive biotherapeutic solutions for cardiovascular disease in its cardiamp™ and cardiallo™ therapies. clinical results supporting both therapeutic programs are compelling and build upon the most rigorous data in the field to date with intramyocardial delivery of marrow-derived cells. these programs are enabled by the company's helix™ transendocardial delivery systems and morph® vascular access products, which are partnered to enable other promising biotherapeutic programs.
BioCardia executives and other stock owners filed with the SEC include: